The type of metastasis is a prognostic factor in disseminated cervical cancer

Journal of Gynecologic Oncology

Volumn 21, Issue 3, 2010, Pages 186-190

  Kim, Kidong ^a   Cho, Soo Youn ^a   Kim, Beob Jong ^a   Kim, Moon Hong ^a   Choi, Seok Cheol ^a   Ryu, Sang Young ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Cancer chemotherapy; Lymphatic metastasis; Neoplasm metastasis; Radiotherapy; Uterine cervical neoplasm

Indexed keywords

CISPLATIN; FLUOROURACIL; LAMININ; METALLOPROTEINASE; PACLITAXEL; TOPOTECAN; TUMOR MARKER; VASCULOTROPIN A;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSEMINATED CANCER; FEMALE; HEMATOGENOUS METASTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LYMPH NODE METASTASIS; MEDICAL RECORD REVIEW; METASTASIS; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RADIATION DOSE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 78049468880     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.3.186     Document Type: Article

References (11)

1. IARC Cancer Epidemiology Database [Internet]. Lyon: International Agency for Research on Cancer; [cited 2009 May 27]. Available from: http://www-dep.iarc.fr/.
2. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95: S43-103.
3. Aziz MF, Gynecological cancer in Indonesia. J Gynecol Oncol 2009; 20: 8-10.
4. Chao A, Ho KC, Wang CC, Cheng HH, Lin G, Yen TC, et al. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. Gynecol Oncol 2008; 110: 172-8.
5. Qiu JT, Ho KC, Lai CH, Yen TC, Huang YT, Chao A, et al. Supraclavicular lymph node metastases in cervical cancer. Eur J Gynaecol Oncol 2007; 28: 33-8.
6. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Trinh XB, Colpaert CG, van Dam P, et al. Comparison of molecular deter-minants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer. J Pathol 2007; 213: 56-64.
7. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, Colpaert C, et al. Differential expression of hypoxia and (lymph)angiogenesis- related genes at different metastatic sites in breast cancer. Clin Exp Metastasis 2007; 24: 13-23.
8. Smith SC, Nicholson B, Nitz M, Frierson HF, Smolkin M, Hampton G, et al. Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hema-togenous dissemination. Am J Pathol 2009; 174: 371-9.
9. Kang S, Kim SK, Chung DC, Seo SS, Kim JY, Nam BH, et al. Diagnostic value of (18)F-FDG PET for evaluation of Paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis. J Nucl Med 2010; 51: 360-7.
10. Horowitz NS, Tamimi HK, Goff BA, Koh WJ, Schmidt RA, Greer BE, et al. Pretreatment scalene node biopsy in gyneco-logic malignancy: prudent or passe? Gynecol Oncol 1999; 75: 238-41.
11. Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 2003; 90: 572-6.